Department of Radiotherapy, Zhuji People's Hospital, Zhuji 311809, Zhejiang Province, China , jiqawrp975@163.com
Abstract: (203 Views)
Background:This study aims to evaluate the clinical efficacy of concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC) following induction chemotherapy (IC) with albumin-bound paclitaxel (ABP) combined with carboplatin, through the analysis of serum biomarkers and dynamic contrast-enhanced magnetic resonance imaging (MRI) data. Material and Methods: Ninety-six NPC patients were rolled into Group I (concurrent chemoradiotherapy) and Group II (IC with ABP and carboplatin+concurrent chemoradiotherapy). DCE-MRI scans were utilized to evaluate changes in lesion characteristics. Serum samples were collected to analyze tumor markers including cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), SCC-associated antigen (SCC-Ag), and carbohydrate antigen 125 (CA-125), as well as superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity, and malondialdehyde (MDA) levels. Toxicities and 2-year overall survival (OS) and progression-free survival (PFS) were also assessed. Results: Group II exhibited a markedly higher objective response rate and disease control rate versus Group I (35.4% vs. 58.3%, 50.0% vs. 81.3%, respectively). MRI scans revealed a drastic reduction in the proportion of patients with obvious enhancement of primary lesions, invasion of the base of the skull/medial pterygoid muscle, etc. Serum levels of CYFRA21-1, SCC-Ag, CA125, and MDA were greatly decreased, while SOD and GSH-Px activities were notably increased (P<0.05). Group II showed a considerable increase in OS and PFS versus Group I (75.0% vs. 89.6%, 68.8% vs. 83.3%, respectively, P<0.05). Conclusion: the combination of ABP and carboplatin has demonstrated enhanced efficacy and improved survival outcomes in patients with NPC, providing new insights and evidence for clinical application.
1. Lee AWM, Ng WT, Chan JYW, et al. (2019) Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev, 79: 101890. DOI: 10.1016/j.ctrv.2019.101890 [DOI:10.1016/j.ctrv.2019.101890]
2. Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, et al. (2023) Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading? Curr Treat Options Oncol, 24(9): 1138-1166. DOI: 10.1007/s11864-023-01101-3 [DOI:10.1007/s11864-023-01101-3]
3. Nazeer F, Poulose JV, Kainickal CT (2022) Induction chemotherapy in nasopharyngeal carcinoma - A systematic review of phase III clinical trials. Cancer Treat Res Commun, 32: 100589. DOI: 10.1016/j.ctarc.2022.100589 [DOI:10.1016/j.ctarc.2022.100589]
4. Fan Y, Hui M, Li F, et al. (2024) Establishment of nomogram prediction model for distant metastasis of nasopharyngeal carcinoma after radiotherapy. Int J Radiat Res, 22(2): 373-378. DOI: 10.61186/ijrr.22.2.373 [DOI:10.61186/ijrr.22.2.373]
5. You R, Liu Y-P, Huang P-Y, et al. (2020) Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: A multicenter phase 3 randomized clinical trial. JAMA Oncol, 6(9): 1345-1352. DOI: 10.1001/jamaoncol.2020.1808 [DOI:10.1001/jamaoncol.2020.1808]
6. Natasya Naili MN, Hasnita CH, Shamim AK, et al. (2010) Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Cancer Genet Cytogenet, 203(2): 309-12. DOI: 10.1016/j.cancergencyto.2010.07.136 [DOI:10.1016/j.cancergencyto.2010.07.136]
7. Smith ER, Wang J-Q, Yang D-H, Xu X-X (2022) Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat, 65: 100881. DOI: 10.1016/j.drup.2022.100881 [DOI:10.1016/j.drup.2022.100881]
8. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 20(7): 924-937. DOI: 10.1016/S1470-2045(19)30167-6 [DOI:10.1016/S1470-2045(19)30167-6]
9. Yuan Y, Lee JS, Yost SE, et al. (2021) Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer. Oncologist, 26(3): e382-e393. DOI: 10.1002/onco.1357 [DOI:10.1002/onco.13574]
10. Parisi A, Palluzzi E, Cortellini A, et al. (2020) First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clin Transl Oncol, 22(1): 158-162. DOI: 10.1007/s12094-019-02122-x [DOI:10.1007/s12094-019-02122-x]
11. Huang Y, Yan D, Wang M, et al. (2021) Clinicopathological factors affecting the prognosis of massive hemorrhage after radiotherapy for patients having nasopharyngeal carcinoma. J Cancer Res Ther, 17(5): 1219-1224. DOI: 10.4103/jcrt.jcrt_586_21 [DOI:10.4103/jcrt.jcrt_586_21]
12. Liu L, Hu L, Zeng Q, Peng D, Chen Z, Huang C, et al. (2021) Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: correlation of quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters with hypoxia-inducible factor 1α expression and tumor grade/stage. Ann Palliat Med, 10(2): 2238-2253. DOI: 10.21037/apm-21-303 [DOI:10.21037/apm-21-303]
13. Hengrui L (2023) An example of toxic medicine used in traditional Chinese medicine for cancer treatment. J Tradit Chin Med, 43(2): 209-210. DOI: 10.19852/j.cnki.jtcm.2023.02.001
14. Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, et al. (2022) Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol, 15(1): 165. DOI: 10.1186/s13045-022-01383-4 [DOI:10.1186/s13045-022-01383-4]
15. Baloche V, Ferrand FR, Makowska A, et al. (2020) Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. Expert Opin Ther Targets, 24(6): 545-558. DOI: 10.1080/14728222.2020.1751820 [DOI:10.1080/14728222.2020.1751820]
16. Mai HQ, Chen QY, Chen D, et al. (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med, 27(9): 1536-1543. DOI: 10.1038/s41591-021-01444-0 [DOI:10.1038/s41591-021-01444-0]
17. Twu CW, Lin PJ, Tsou HH, et al. (2022) Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma. Head Neck, 44(6): 1453-1461. DOI: 10.1002/hed.27044 [DOI:10.1002/hed.27044]
18. Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. (2022) Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol, 8(5): 706-714. DOI: 10.1001/jamaoncol.2022.0122 [DOI:10.1001/jamaoncol.2022.0122]
19. Takeshita N, Enokida T, Okano S, et al. (2022) Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study. Front Oncol, 12: 951387. DOI: 10.3389/fonc.2022.951387 [DOI:10.3389/fonc.2022.951387]
20. Luo DH, Li XY, Guo SS, et al. (2023) Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA-IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial. Lancet Reg Health West Pac, 40: 100895. DOI: 10.1016/j.lanwpc.2023.100895 [DOI:10.1016/j.lanwpc.2023.100895]
21. Sharifi-Rad J, Quispe C, Patra JK, et al. (2021) Paclitaxel: Application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev, 2021: 3687700. DOI: 10.1155/2021/3687700 [DOI:10.1155/2021/3687700]
22. Liu H and Li Y (2022) Potential roles of Cornichon family AMPA receptor auxiliary protein 4 (CNIH4) in head and neck squamous cell carcinoma. Cancer Biomark, 35(4): 439-450. DOI: 10.3233/CBM-220143 [DOI:10.3233/CBM-220143]
23. Ke LR, Xia WX, Qiu WZ, et al. (2017) A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. Oral Oncol, 70: 7-13. DOI: 10.1016/j.oraloncology.2017.04.018 [DOI:10.1016/j.oraloncology.2017.04.018]
24. Thawani R, Gao L, Mohinani A, Tudorica A, Li X, Mitri Z, et al. (2022) Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. BMC Med Imaging, 22(1): 182. DOI: 10.1186/s12880-022-00908-0 [DOI:10.1186/s12880-022-00908-0]
25. Militello C, Rundo L, Dimarco M, et al. (2022) 3D DCE-MRI radiomic analysis for malignant lesion prediction in breast cancer patients. Acad Radiol, 29(6): 830-40. DOI: 10.1016/j.acra.2021.08.024 [DOI:10.1016/j.acra.2021.08.024]
26. Filella X, Rodríguez-Garcia M, Fernández-Galán E (2022) Clinical usefulness of circulating tumor markers. Clin Chem Lab Med, 61(5): 895-905. DOI: 10.1515/cclm-2022-1090 [DOI:10.1515/cclm-2022-1090]
27. Jiang M, Chen P, Guo X, et al. (2023) Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag. EJNMMI Res, 13(1): 27. DOI: 10.1186/s13550-023-00976-5 [DOI:10.1186/s13550-023-00976-5]
28. Choi KH, Yu M, Jeong S, Lee JH (2020) Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis. Int J Clin Oncol, 25(7): 1405-1411. DOI: 10.1007/s10147-020-01664-3 [DOI:10.1007/s10147-020-01664-3]
29. Gebhart P, Singer CF, Gschwantler-Kaulich D. (2023) CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study. BMC Cancer, 23(1): 610. DOI: 10.1186/s12885-023-11116-6 [DOI:10.1186/s12885-023-11116-6]
30. Li S, Pi G, Zeng Y, et al. (2022) Notoginsenoside R1 induces oxidative stress and modulates LPS induced immune microenvironment of nasopharyngeal carcinoma. Int Immunopharmacol, 113(Pt A): 109323. DOI: 10.1016/j.intimp.2022.109323 [DOI:10.1016/j.intimp.2022.109323]
31. Qiu W, Jiang J, Zhan Z, et al. (2022) Prognostic impact of pretreatment serum superoxide dismutase activity in patients with locoregionally advanced nasopharyngeal carcinoma. Int J Biol Markers, 37(1): 21-30. DOI: 10.1177/17246008221075042 [DOI:10.1177/17246008221075042]
32. Gao H, Xie R, Huang R, et al. (2022) CIRBP regulates pancreatic cancer cell ferroptosis and growth by directly binding to p53. J Immunol Res, 2022: 2527210. DOI: 10.1155/2022/2527210 [DOI:10.1155/2022/2527210]
33. Amina G, Hasnae D, Imane EA, et al. (2022) Assessment of lipid peroxidation status in the serum of Moroccan patients with nasopharyngeal carcinoma. Contemp Oncol (Pozn), 26(4): 253-258. DOI: 10.5114/wo.2023.124498 [DOI:10.5114/wo.2023.124498]
34. Chen L, Hu CS, Chen XZ, et al. (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol, 13(2): 163-71. DOI: 10.1016/S1470-2045(11)70320-5. [DOI:10.1016/S1470-2045(11)70320-5]
Huang M, Wang G, Xuan F. Clinical efficacy of albumin-bound paclitaxel combined with carboplatin in the treatment of nasopharyngeal carcinoma. Int J Radiat Res 2025; 23 (2) :427-433 URL: http://ijrr.com/article-1-6403-en.html